Protocol Ledger

NCT07161037 · Phase II · ACTIVE NOT RECRUITING

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Interventional Phase II clinical trial protocol NCT07161037 sponsored by Vertex Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-19 Enrollment: 26 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07161037
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)26 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07161037
Protocol FieldVerified Registry Value
NCT IdentifierNCT07161037
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment26 participants (ACTUAL)
Registered Start Date2025-11-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI